| Trade Names: | |
| Synonyms: | |
| Status: | Approved (2019) |
| Entry Type: | Small molecule |
| Molecule Category: | UNKNOWN |
| ATC: | L02BB06 |
| UNII: | X05U0N2RCO |
| InChI Key | BLIJXOOIHRSQRB-PXYINDEMSA-N |
|---|---|
| Smile | |
| InChI |
|
| Property Name | Value |
|---|---|
| Molecular Formula | C19H19ClN6O2 |
| Molecular Weight | 398.85 |
| AlogP | 2.67 |
| Hydrogen Bond Acceptor | 6.0 |
| Hydrogen Bond Donor | 3.0 |
| Number of Rotational Bond | 6.0 |
| Polar Surface Area | 119.62 |
| Molecular species | NEUTRAL |
| Aromatic Rings | 3.0 |
| Heavy Atoms | 28.0 |
| Primary Target | |
|---|---|
| Androgen receptor |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Transcription factor
Nuclear receptor
Nuclear hormone receptor subfamily 3
Nuclear hormone receptor subfamily 3 group C
Nuclear hormone receptor subfamily 3 group C member 4
|
- | 26 | - | 11 | - |
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Prostatic Neoplasms | 4 | D011471 | ClinicalTrials |
| Prostatic Neoplasms | 4 | D011471 | ClinicalTrials |
| Prostatic Neoplasms | 4 | D011471 | ClinicalTrials |
| Neoplasms | 4 | D009369 | ClinicalTrials |
| Prostatic Neoplasms, Castration-Resistant | 3 | D064129 | ClinicalTrials |
| Breast Neoplasms | 2 | D001943 | ClinicalTrials |
| Resources | Reference |
|---|---|
| CAS NUMBER | 1297538-32-9 |
| ChEMBL | CHEMBL4297185 |
| DrugBank | DB12941 |
| FDA SRS | X05U0N2RCO |
| Guide to Pharmacology | 10439 |
| PubChem | 67171867 |
| SureChEMBL | SCHEMBL1814935 |